DESTINY-Breast02: high levels of efficacy of T-DXd in previously treated HER2+ breast cancer

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previo...Подробнее

DESTINY-Breast03: T-DXd is superior to T-DM1 in HER2+ metastatic breast cancerПодробнее

Dr Lin on the Efficacy of T-DXd in HER2+ Advanced Breast Cancer With CNS MetastasesПодробнее

Cancer and Us gets a port for breast cancer HER2 Positive Chemo treatmentПодробнее

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1Подробнее

Highlights on T-DXd in pretreated HER2-expressing solid tumours : The DESTINY-PanTumor02 studyПодробнее

Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancerПодробнее

DESTINY-Gastric02: T-Dxd as a second-line treatment for HER2-positive gastric cancerПодробнее

Updated findings of T-DXd in DESTINY-Breast02 at ESMO Breast 2024Подробнее

DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markersПодробнее

DEBBRAH: T-DXd in HER2+ or HER2-low advanced breast cancer with CNS involvementПодробнее

Dr Curigliano on the Efficacy of T-DXd in HER2-Low and HER2-Ultralow Breast CancerПодробнее

Updated analysis of DESTINY-Gastric02: T-DXd in HER2+ GEJ cancer who progressed with trastuzumabПодробнее

Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancerПодробнее

DESTINY-Breast12: T-DXd in patients with HER2+/HR- breast cancer with brain metastasisПодробнее

SABCS 2022: DESTINY-Breast02 + DESTINY-Breast03Подробнее

ASCO23 - LBA3000: Efficacy and safety T-DXd in HER2-expressing solid tumors: DESTINY-PanTumor02 ...Подробнее

DESTINY-Gastric02: 2L T-DXd in HER2+ gastric cancersПодробнее

DESTINY-Breast04: T-DXd for patients with HER2-low mBCПодробнее